Skip to main content

News

Antidepressants for Pain are Weakly Effective

EurekAlert!
University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence. The study found that in the last 40 years there have been only 15 trials globally focusing on the benefit of antidepressants for pain in older people. This study fills a much-needed gap in research by bringing together the information from these trials to look at the efficacy and harms of antidepressants for acute and chronic non-cancer pain in those over 65 years old.

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).

Increased Cardiovascular Events in Lupus

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

BSR Guidelines for Systemic Sclerosis Management

The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion. 

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.

Systemic Sclerosis Insights (9.13.2024)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Increasing Incidence of Morphea

A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.

ACR Speaks Against Repeated Cuts to Medicare Reimbursements

ACR
The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.

Low Placental Transfer Rates with Risankizumab

There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research. 

ACR Recommends QOL Self-Management Strategies

ACR

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a

Consensus Guidelines on Pediatric Methotrexate Use

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Moving Forward on RA Prevention Trials

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

×